The investigational drugs E7820, indisulam and tasisulam (aryl-sulfonamides) promote the degradation of the splicing factor RBM39 in a proteasome-dependent mechanism. While the activity critically depends on the cullin RING ligase substrate receptor DCAF15, the molecular details remain elusive. Here we present the cryo-EM structure of the DDB1-DCAF15-DDA1 core ligase complex bound to RBM39 and E7820 at a resolution of 4.4 Å, together with crystal structures of engineered subcomplexes. We show that DCAF15 adopts a new fold stabilized by DDA1, and that extensive protein-protein contacts between the ligase and substrate mitigate low affinity interactions between aryl-sulfonamides and DCAF15. Our data demonstrate how aryl-sulfonamides neo-functionalize a shallow, non-conserved pocket on DCAF15 to selectively bind and degrade RBM39 and the closely related splicing factor RBM23 without the requirement for a high-affinity ligand, which has broad implications for the de novo discovery of molecular glue degraders.
P harmacologic intervention for many newly discovered disease targets-such as transcription factors, multiprotein complexes or scaffold proteins-is challenging because they lack an enzymatic function to facilitate the design of classical lowmolecular-weight inhibitors. An alternative approach, small molecule-induced protein degradation, circumvents the need for an enzymatic function in the target protein 1 . The therapeutic potential of targeted protein degradation has been demonstrated by the success of thalidomide-related anticancer drugs (often referred to as immunomodulatory drugs or IMiDs). IMiDs bind CRBN, the substrate receptor of the CUL4-RBX1-DDB1-CRBN (CRL4 CRBN ) E3 ubiquitin ligase [2] [3] [4] [5] , and generate a binding surface to recruit and ubiquitinate neo-substrates [6] [7] [8] [9] [10] . Such molecular glues present an opportunity to target virtually any protein for degradation, even in the absence of a defined binding pocket. However, IMiDs have nanomolar affinity for CRBN, and the almost invariable conservation of the drug-binding pocket and neo-substrate interaction surface suggests that IMiDs hijack an evolutionarily conserved mechanism, akin to what was found for the plant hormones auxin and jasmonate 11, 12 . Whether molecular glue degraders critically depend on such high-affinity interactions, and whether these interactions can be achieved for ligases that have not evolved for ligand binding, is of critical importance for the further development of this new therapeutic modality.
Recently, the aryl-sulfonamides E7820 (1), indisulam (2) and tasisulam (3) were shown to induce targeted degradation of the splicing factor RBM39 through recruitment of the E3 ubiquitin ligase CUL4-RBX1-DDB1-DCAF15 (CRL4 DCAF15 ) 13, 14 , which suggested a molecular glue mechanism. Indisulam was initially discovered in a phenotypic screen and found to be cytotoxic to specific cancer cell lines and in preclinical models 15 , while tasisulam and E7820 are derivatives around the sulfonamide core. E7820, indisulam and tasisulam were investigated in multiple phase I and II clinical trials involving advanced-stage solid tumors with a modest number of clinical responses, potentially owing to an insufficient understanding of the mechanism of action and lack of informed patient stratification 14, 16 . However, new genetic dependencies in acute myeloid leukemia (AML) suggest a potential for clinical development 16 , and a recent phase II study encourages development with appropriate biomarkers 17 . Moreover, the aryl-sulfonamides appear to promote binding of DCAF15 to the RNA-recognition motif (RRM) of RBM39, which suggests that derivatives of the aryl-sulfonamides may be used to target other RRM-containing proteins 9, 10 . However, a detailed picture of the mechanism by which sulfonamides engage CRL4 DCAF15 to promote turnover of the neosubstrate RBM39 is required to further leverage this new class of drugs for the targeting of RBM39 (and more generally of RRMcontaining proteins), and for the broad application of molecularglue degraders. We therefore set out to dissect the molecular basis of RBM39 recruitment to CRL4 DCAF15 .
Results

RBM39 recruitment to CRL4 DCAF15 depends on sulfonamides.
A recent study identified resistance mutations in cells treated with cytotoxic doses of indisulam that arise in the second RRM domain of RBM39 (RBM39 RRM2 ) 13, 14 . These mutations abrogate the interaction with CRL4 DCAF15 , which suggested that ligase binding is mediated by the RRM2 domain. To better characterize the interaction of RBM39 with DCAF15, we measured the affinity of recombinant DDB1-DCAF15 for RBM39 RRM2 in the presence of E7820 using time-resolved Förster resonance energy transfer (TR-FRET). In the presence of E7820, indisulam or tasisulam at 50 µM, DDB1-DCAF15 and RBM39 RRM2 associated with K D app values of 2.0 µM, 2.1 µM or 3.5 µM, respectively ( Fig. 1a and Supplementary Fig. 1a ). By contrast, RBM39 RRM2 did not show measurable affinity with DDB1-DCAF15, even at 10 µM, in the absence of compound ( Supplementary  Fig. 1b ). E7820 interacts with DCAF15 (K D app = 3.8 µM), but not with RBM39 ( Fig. 1b and Supplementary Fig. 1c ). On the basis of TR-FRET competition assays ( Supplementary Fig. 1d ,e), E7820 binds to DCAF15 with a K i of 2.9 µM, while the K i for indisulam and tasisulam is >50 µM (Fig. 1c ), which is analogous to the half maximal effective concentration (EC 50 ) values when each DDB1∆B was readily placed into the density using the crystal structure (Protein Data Bank (PDB) accession 5FQD, chain A) as a model, and a search using the BALBES-MOLREP pipeline 19 located the RRM domain corresponding to RBM39 RRM2 (Fig. 1e ) but did not identify homologous structures in the putative fulllength DCAF15 density. The map allowed for segmentation of the density and unambiguous assignment of density to DCAF15 and DDA1 ( Fig. 1d,e ). While the resolution was not sufficient to build an atomic model ( Supplementary Fig. 3a ), we were able to build an approximate polyalanine trace of DCAF15 and DDA1 using additional information from crosslinking mass spectrometry (MS; Supplementary Table 1 ), mutations placed in putative helices ( Supplementary Fig. 4a ) and secondary structure prediction. RBM39 RRM2 packs against an α-helix of DCAF15 and the Gly268 of RBM39, which was previously found to be a dominant position of indisulam resistance mutations 13, 14 , packs against the DCAF15 helix and would not tolerate a side-chain-bearing residue ( Fig. 1e ). At the interface between RBM39 RRM2 and DCAF15, a density that did not represent amino acid side chains was present and was tentatively c, Competitive titration of BodipyFL-E7820 (4) with aryl-sulfonamides in a Tr-FrET assay. DDB1∆B-DCAF15 biotin is at 200 nM, BodipyFL-E7820 (4) is at 5 µM and aryl-sulfonamides are at 0.002-100 µM. Tr-FrET data in a-c are plotted as mean ± s.d. from three independent replicates (n = 3). d, Cryo-EM map (resolution of 4.4 Å) of the DDB1∆B-DCAF15-DDA1-E7820-rBM39 rrM2 complex segmented to indicate DDA1 (cyan), DCAF15 (green), rBM39 rrM2 (magenta), DDB1-BPC (orange), DDB1-BPA (red) and DDB1-CTD (gray). e, Cryo-EM map shown with the fitted and refined model. right, close-up of the region of the rBM39-DCAF15 interface, with the resistance mutation site G268V indicated in yellow and the putative E7820 density outlined in dotted lines. f, Domain representation of the proteins present in the complex. regions omitted from the constructs are indicated by hatched lines. assigned as E7820 ( Fig. 1e ). While the proximity of RBM39 residue Met265, which when substituted to leucine abrogates binding 14 , supports this assignment, the resolution of the cryo-EM map was insufficient for an unambiguous interpretation of ligand binding.
We therefore engineered a minimal complex suitable for crystallographic studies. Limited proteolysis experiments revealed that similarly sized fragments of DCAF15 were stably associated with DDB1 after gel filtration ( Supplementary Fig. 4b ). This result indicated both that DCAF15 contained an exposed, likely disordered, region available for proteolytic cleavage and that distinct segments of DCAF15 could independently bind DDB1. Disorder prediction further demonstrated a highly unstructured region of DCAF15 ( Supplementary Fig. 4c ), which led us to design constructs of the N-terminal (residues 30-264) and C-terminal (residues 383-600) fragments of human DCAF15 (DCAF15 split ). Simultaneous expression of these fragments with DDB1∆B led to the formation of a soluble complex that exhibited equivalent binding affinity for RBM39 to full-length human DCAF15 ( Supplementary Fig. 4d,e ).
Crystal structure of DCAF15 complex bound to RBM39 RRM2 . Crystals were obtained for a DDB1∆B-DCAF15 split -DDA1-E7820-RBM39 RRM2 complex and the structure was determined by molecular replacement with a final model refined to a resolution of 2.9 Å ( Fig. 2a and Supplementary Table 2 ). To validate that the engineered DCAF15 split resembles the full-length DCAF15 structure, we docked the X-ray model into the cryo-EM map 20 and found that the crystal structure accounts for all of the full-length DCAF15 density, as well as density for E7820 ( Supplementary Fig. 3e ,f).
DCAF15 split consists of two predominantly β-sheet-containing domains (Fig. 2b,c) , the N-terminal domain (NTD; residues 30-264) and the C-terminal domain (CTD; residues 383-600). DCAF15 binds to DDB1 with a helix-loop-helix motif 21 , forming contacts with the two DDB1 β-propeller domains BPA and BPC and resembling the helix-loop-helix motif in CSA and DDB2 (Supplementary Figs. 4a and 5a,b). DCAF15, unlike most other DDB1 and CUL4associated factors (DCAFs), does not contain a canonical WD40 β-propeller fold and lacks homology to any other CRL substrate receptor 22 . A zinc ion is coordinated by Cys193, Cys196, Cys211 and His214 (Fig. 2 ). Following the helix-loop-helix motif, the DCAF15-NTD and CTD are interwoven into five stacks of antiparallel β-sheets in an open solenoid arrangement, with β-sheets 1, 3 and 4 sharing strands from both the NTD and CTD. While β-sheets 2 and 3 have some resemblance to WD40 repeats, β-sheets 4 and 5 have unique features (Fig. 2b,c) . Preceding β-sheet 4 is a short helix . E7820 (yellow) and zinc (tan) are shown as spheres. right, a different view of the complex, shown in transparent surface representation. b, Cartoon representation of DCAF15 indicating secondary structure elements and colored in blue and green for the DCAF15-nTD and DCAF15-CTD, respectively. DCAF15 α-helices and β-strands are numbered from the n to C terminus, which are shown as colored circles for both the nTD and CTD of DCAF15. c, Cartoon view of DCAF15, highlighting the five stacked β-sheets. Helices from the nTD and CTD are colored in gray.
(α4) angled ~45° away from the sheet, before looping into β-strands 10 and 11. The terminal strands 12 and 14 of β-sheet 4 are contributed by the DCAF15-CTD, creating an extended interface between the two domains. β-sheet 5 is stabilized by two α-helices (DCAF15 α5 and α6), and α7 helix sits on the opposite side forming the major interactions with RBM39 RRM2 . The overall shape of DCAF15 is clamp-like and embraces RBM39 RRM2 on the concave surface.
The small protein DDA1 is commonly associated with CRL4 complexes 23, 24 , and knockout of DDA1 was found to reduce the indisulam-mediated degradation of RBM39 14 . In the crystal and cryo-EM structures, DDA1 binds to the top of the DDB1-BPA before running down the back side of the propeller (Figs. 1d  and 3a ). At the bottom of the DDB1-BPA, DDA1 intercalates a β-strand in the DDB1 propeller, using several highly conserved residues ( Fig. 3b ). Adjacent to this β-strand is an α-helix that buries multiple DDA1 hydrophobic residues (Leu55, Leu56, Leu59 and Trp63) in DCAF15 ( Fig. 3b ). Given that DDA1 is a core CRL4 component associating with many different substrate receptors 23, 25 , the extent of the DCAF15 interactions are unexpected and suggest that the DDA1 helix represents a plastic binding module for other DCAFs. We measured the affinity of E7820 for recombinant DDB1-DCAF15 and DDB1-DCAF15-DDA1, as well as the ability of these complexes to bind to RBM39 RRM2. While the affinity of E7820 to DCAF15 was not altered by the presence of DDA1, the apparent affinity to RBM39 RRM2 was strengthened approximately threefold to a K D app of 0.62 µM ( Fig. 3c-e ), which explains why genetic loss of DDA impairs induced RBM39 degradation 14 . Aryl-sulfonamides interact primarily with DCAF15. E7820 binds in a shallow pocket at the interface between DCAF15-NTD and DCAF15-CTD that is situated in a weakly conserved surface groove proximal to DDB1 ( Fig. 4 and Supplementary Fig. 5c-e ). While the placement of E7820 is firmly supported by the electron density ( Supplementary Fig. 6a ,b), we further validated the arrangement of the ligand through anomalous diffraction and a UV-crosslinking probe ( Supplementary Fig. 6c -h). E7820 is sandwiched in a hydrophobic pocket between DCAF15 and RBM39 RRM2 , with the indole facing Met265 of RBM39. Notably, the RBM39 Met265Leu substitution was found to confer resistance to E7820-mediated degradation 14 , which is in accordance with the sulfur-π interaction observed in the structure. The two sulfonyl oxygens of E7820 form hydrogen bonds with the backbone amide nitrogens of DCAF15 Ala234 and Phe235, while the indole nitrogen and sulfonamide nitrogen form extensive water-mediated hydrogen bonds with the side-chain oxygens of RBM39 Thr262 and Asp264. Additional hydrogen bonds between the indole nitrogen and backbone carbonyl oxygen of DCAF15 Phe231, together form the core pharmacophore. The C4 methyl of E7820 forms hydrophobic interactions with Val477 and Val556 of DCAF15 (Fig. 4a,c) , and swapping the methyl for a hydrogen, as in indisulam or desmethyl-E7820, results in a substantial loss of DCAF15 binding ( Supplementary Fig. 6i ). The phenyl ring forms a T-shaped π-π interaction with DCAF15 Phe235 and otherwise is situated in a spacious pocket allowing for structural diversity as observed in indisulam and tasisulam.
Finally, we obtained structures of the related but structurally distinct analogs indisulam and tasisulam to a resolution of 2.9 Å ( Fig. 4d and Supplementary Fig. 6j ,k). We found that indisulam and tasisulam bind DCAF15 in an overall configuration similar to E7820, maintaining the backbone hydrogen bonds from the sulfonyl groups to DCAF15 Ala234 and Phe235 and the water-mediated hydrogen bonds. However, the methyl-to-hydrogen substitution at C4 in indisulam limits the hydrophobic interactions with DCAF15 (3). c, E7820 interacts predominantly through the sulfonamide moiety and the indole moiety with residues in the DCAF15-nTD (blue). Additional hydrophobic interactions with the DCAF15-CTD (green) and sulfur-π interactions, as well as water (cyan)-mediated hydrogen bonds with rBM39 (magenta), stabilize E7820 in a shallow pocket. d, Surface representation of DCAF15 is shown in gray and E7820, indisulam and tasisulam are shown as stick representation in yellow, magenta and cyan, respectively.
Val477 and Val556, while tasisulam lacks the indole NH hydrogen bond to the backbone carbonyl of DCAF15 Phe231 ( Supplementary  Fig. 6j ,k). These differences in indisulam and tasisulam help to explain their loss in affinity for DCAF15, while maintaining the ability to recruit RBM39 for degradation ( Fig. 1a,c) .
DCAF15-RBM39 forms extensive protein-protein contacts.
The weak affinity of aryl-sulfonamides for DCAF15 ( Supplementary  Fig. 1c ,f) suggests that protein-protein contacts between DCAF15 and RBM39 RRM2 stabilize the interaction. RBM39 RRM2 presents itself as a canonical RRM fold, comprised of a four-stranded antiparallel β-sheet (β1-β4) stacked on two α-helices (α1 and α2) ( Fig. 2a ) and
interacts with DCAF15 predominantly via the two α-helices. The RBM39 RRM2 α1 helix docks into the surface groove on DCAF15 that also harbors the E7820-binding site and forms contacts with DCAF15 and E7820. The RBM39 RRM2 -DCAF15 interface comprises ~1,150 Å 2 and spans the DCAF15-NTD and CTD (Fig. 5a ). The binding groove is not conserved ( Supplementary Fig. 5e ) and is dominated by extensive hydrophobic interactions with the DCAF15 α7 helix in the CTD (Fig. 5b ). As was observed in the cryo-EM structure (Fig. 1e ), the tight packing of the interface would not allow a side-chain-bearing residue at RBM39 Gly268, such that a Gly268Val substitution completely abrogates RMB39 RRM2 recruitment to DCAF15 ( Supplementary Fig. 6l ). The interface includes four salt bridges between DCAF15 Arg574, Arg178, Arg160 and Asp174 and RBM39 Asp264, Glu271 and Arg275, respectively, and side-chain hydrogen bonds between DCAF15 Ser546 and RBM39 Gln310 (Fig. 5b ). An additional indisulam resistance substitution in RBM39, Glu271Gln 14 , is likely explained by a loss in the saltbridge interaction with DCAF15 ( Supplementary Fig. 6m ). An extended network of backbone hydrogen bonds further stabilizes the DCAF15-RBM39 interface ( Supplementary Fig. 6n ).
Aryl-sulfonamides selectively degrade RBM39 and RBM23. As many RRM domains are structurally highly similar, and as RBM39 interacts with DCAF15 predominantly through two conserved α-helices in its second RRM, we considered whether other RRMcontaining proteins would be targeted by DCAF15 and E7820. To assess the degradome of E7820, we performed unbiased MS-based proteomics experiments and found that, other than RBM39, RBM23 was the only protein to be degraded of ~11,000 proteins detected (Fig. 5c ). Sequence analysis revealed that the second RRM domain of RBM23 (RBM23 RRM2 ) is nearly identical to RBM39 RRM2 , with 100% sequence identity across all key residues that form contacts with DCAF15 and E7820 (Fig. 5d ). Consequently, we found comparable binding affinity for RBM23 RRM2 to that observed for RBM39 RRM2 (Fig. 5e ). Cullin RING ligases of the CRL4 family tolerate a diverse set of substrate receptors but typically present their substrates in a canonical position 21, 26 . When superimposed with a cullin RING ligase complex (PDB accession 4A0K), a model of the full CRL4 DCAF15 ligase bound to RBM39 can be constructed. RBM39 RRM2 is bound to a face of DCAF15 that is not directly opposed to RBX1 (Fig. 6a) , however the N and C termini of RBM39 are positioned toward RBX1, and could tolerate additional domains at both positions. Furthermore, in contrast to CRBN, the ligand and substrate pocket of DCAF15 is not conserved (Fig. 6b ), suggesting that the topological and evolutionary constraints on developing molecular glue degraders are rather flexible.
Discussion
Small molecules that recruit neo-substrates to a ubiquitin ligase have the potential to overcome the need for distinct binding pockets on target proteins. Our structural and pharmacological analyses have uncovered that aryl-sulfonamides represent a new type of molecular glue degrader, as they act as interface binders with weak receptor affinity to promote RBM39 degradation by CRL4 DCAF15 . We find that DCAF15 adopts a structure not commonly found in CRL substrate receptors and engages the second RRM domain of RBM39 with an extended, non-conserved surface area, which is in contrast to other small molecule-mediated CRL-substrate interactions such as auxin, jasmonate and IMiDs 10-12,18,27 . The total buried surface area of RBM39 RRM2 -DCAF15 is 1,150 Å 2 , which is larger
CRBN-lenalidomide-CK1α
Conservation High Low than that of CRBN with neo-substrates (~600 Å 2 ) and compensates for the weak affinity of these compounds for DCAF15 (K i > 50 µM for indisulam and tasisulam). While IMiDs target a β-hairpin loop primarily through backbone interactions between ligand, ligase and neo-substrate, the interactions between RBM39 RRM2 and DCAF15 are more substantial and involve side-chain interactions that result in increased specificity as compared to the relatively promiscuous zinc-finger recognition by the CRBN-IMiD complex 9, 10 . The IMiDbinding pocket is highly conserved, suggesting the existence of a natural ligand, while the pocket in DCAF15 is less conserved, which implies that aryl-sulfonamides bind to an otherwise non-functional cavity. Together, the neo-functionalization of a relatively shallow, non-conserved pocket, and the weak affinity for DCAF15 suggests that molecular glues can be obtained for ligases that are not endogenously regulated by small molecules. Induced protein degradation through proteolysis-targeting chimeras (PROTACs) is another commonly used strategy for protein degradation and new E3 ligase ligands are highly sought after for the development of such probes. The position of the binding pocket in DCAF15, which exposes the phenyl moiety to the solvent proximal to DDB1, together with the relatively weak affinity of aryl-sulfonamides for DCAF15, suggests that these ligands may not be ideally suited for the development of such degraders. While we demonstrate that a linker can be attached to the phenyl ring without significant loss of affinity, the exit vector is pointing toward DDB1 and away from RBX1, which will likely result in steric clashes with target proteins and suboptimal positioning of recruited target proteins to be ubiquitinated.
Our work identifies DDA1 as an integral component of the CRL4 DCAF15 ubiquitin ligase, and we demonstrate how DDA1 serves as an additional scaffolding subunit of a functional CRL4 complex. In the case of CRL4 DCAF15 , DDA1 binds to the top of the BPA subunit of DDB1 and forms extensive contacts with the back side of DDB1 before connecting to DCAF15 through an α-helix, enforcing the overall structure of the complex. The presence of DDA1 causes increased E7820-dependent binding of DCAF15 to RBM39 RRM2 , which is in accordance with DDA1 knockout resulting in partial rescue of RBM39 degradation in cells 14 . It is conceivable that DDA1 will serve as a scaffolding protein in other CRL4 complexes, but more work is needed to understand the role of DDA1 in CRL4 regulation and its potential interplay with other CRL regulators such as the COP9 signalosome and CAND1.
In summary, this work expands our understanding of general principles of molecular glue degraders. We show how binders targeted to interfaces with substantial side-chain interactions between receptor and substrate result in very selective agents. This is in contrast to IMiDs, which bind a conserved pocket in CRBN and only contribute minor backbone interactions to the interface, resulting in highly polytargeted molecules 9, 10 . While close analogs of E7820 are unlikely to target a broad set of RRM domains, the structural complementarity between DCAF15 and the canonical RRM fold suggests that new chemical matter to target other RRM-containing proteins to CRL4 DCAF15 will likely be obtainable. Importantly, our structural characterization further supports the concept that compatible interfaces are more likely to occur between unrelated proteins than we may have anticipated. As such, prospective screens for molecular glues would ideally be preceded by selecting ligases with complementary interfaces for the intended target, similar to what we have previously utilized for PROTAC design 28 .
online content
Any methods, additional references, Nature Research reporting summaries, source data, extended data, supplementary information, acknowledgements, peer review information; details of author contributions and competing interests; and statements of data and code availability are available at https://doi.org/10.1038/s41589-019-0378-3.
Methods
Constructs and protein purification. The human genes for full-length DDB1, DDB1∆B (residues 396-705 replaced with a GNGNSG linker), full-length DCAF15, DCAF15-NTD (residues 30-264), DCAF15-CTD (residues 383-600), full-length DDA1, RBM39 RRM2 (residues 245-332) and RBM23 RRM2 (263-341) and the Xenopus tropicalis gene for full-length DCAF15 were cloned in pACderived vectors 30 . Baculovirus for protein expression (Invitrogen) was generated by transfection into Spodoptera frugiperda (Sf9) cells at a density of 0.9 × 10 6 cells per milliliter grown in ESF 921 medium (Expression Systems), followed by three rounds of infection in Sf9 cells to increase viral titer. Recombinant proteins were expressed as N-terminal His 6 Limited proteolysis and gel filtration. The complex of DDB1ΔB and X. tropicalis DCAF15 complex was diluted to 20 µM in 25 mM HEPES, pH 7.4, 200 mM NaCl and 1 mM TCEP. X. tropicalis DCAF15 is closely related to Homo sapiens DCAF15 (66% sequence identity overall and 76% sequence identity in the structured NTD and CTD regions), and was examined in parallel in initial biochemical experiments. A 200 µM stock of chymotrypsin was diluted to 20 µM with 1 mM HCl and 2 mM CaCl 2 , which was then added to the to complex of DDB1ΔB and X. tropicalis DCAF15 complex at a 400:1 ratio (50 nM chymotrypsin final concentration). The proteolysis reaction was carried out on ice for 45 min, centrifuged at 15,000 rpm at 4 °C and injected onto an EnRich 650 column for gel filtration.
Biotinylation of DCAF15 and RBM39.
Purified Strep-II-Avi-tagged human DCAF15 variants or RBM39 RRM2 were biotinylated in vitro at a concentration of 5-50 µM by incubation with final concentrations of 2.5 µM BirA enzyme and 0.2 mM d-biotin in 50 mM HEPES, pH 7.4, 200 mM NaCl, 10 mM MgCl 2 , 0.25 mM TCEP and 20 mM ATP. The reaction was incubated for 1 h at room temperature and stored overnight at 4 °C. Biotinylated proteins were purified by gel-filtration chromatography and flash frozen in liquid nitrogen and stored at −80 °C.
BodipyFL labeling of RBM39 and RBM23. Purified human RBM39 RRM2 or RBM23 RRM2 was incubated with dithiothreitol (8 mM) at 4 °C for 1 h. Dithiothreitol was removed using a S200 10/300 gel filtration column in a buffer containing 50 mM Tris, pH 7.3 and 150 mM NaCl. BodipyFL-maleimide (Invitrogen) was dissolved in 100% DMSO and mixed with RBM39 or RBM23 to achieve threefold molar excess of BodipyFL-maleimide. Labeling was carried out at room temperature for 3 h and stored overnight at 4 °C. Labeled RBM39 or RBM23 was purified on a S200 10/300 gel filtration column in 50 mM Tris, pH 7.5, 150 mM NaCl, 0.25 mM TCEP, concentrated by ultrafiltration (Milipore), flash frozen in liquid nitrogen and stored at −80 °C.
Time-resolved Förster resonance energy transfer.
Titrations of compounds to induce DCAF15-RBM39 or DCAF15-RBM23 complex were carried out by mixing 200 nM biotinylated Strep-II-Avi-tagged DCAF15, 200 nM BodipyFL-labeled RBM39 or RBM23 variants and 2 nM terbium-coupled streptavidin (Invitrogen) in an assay buffer containing 50 mM Tris, pH 8.0, 200 mM NaCl, 0.1% Pluronic F-68 solution (Sigma) and 0.5% BSA (wt/vol). Full-length human DCAF15 was used in all TR-FRET assays. After dispensing the assay mixture, increasing concentrations of compounds were dispensed in a 384-well microplate (Corning, 4514) using a D300e Digital Dispenser (HP) normalized to 2% DMSO. Before TR-FRET measurements were conducted, the reactions were incubated for 15 min at room temperature. After excitation of terbium fluorescence at 337 nm, emission at 490 nm (terbium) and 520 nm (BodipyFL) were recorded with a 70-μs delay over 600 μs to reduce background fluorescence, and the reaction was followed over 60 cycles of each data point using a PHERAstar FS microplate reader (BMG Labtech). The TR-FRET signal of each data point was extracted by calculating the 520/490 nm ratio. The EC 50 values calculated using the [agonist] versus response (three parameters) equation in GraphPad Prism 7.
Titrations of BodipyFL-RBM39 were carried out by mixing 400 nM biotinylated Strep-II-Avi-tagged DCAF15 variants, 100 μM compounds or an equivalent volume of DMSO and 4 nM terbium-coupled streptavidin in the same assay buffer. After dispensing the assay mixture, an increasing concentration of BodipyFL-RBM39 was added to the compound-bound DCAF15 in a 1:1 volume ratio and incubated for 15 min at room temperature. The 520/490 nm ratios were plotted to calculate the K d values estimated using the one-site-specific binding equation in GraphPad Prism 7.
Titrations of BodipyFL-E7820 (4) were carried out by mixing 200 nM biotinylated Strep-II-Avi-tagged DCAF15 variants or an equivalent volume of the assay buffer, 2 nM terbium-coupled streptavidin in the same assay buffer. After dispensing the assay mixture, an increasing concentration of BodipyFL-E7820 (4) was dispensed in the 384-well plate using a D300e Ditial Dispenser normalized to 2% DMSO and then incubated for 15 min at room temperature. The 520/490 nm ratios from the sample with DCAF15 was subtracted by the ratios from the sample without DCAF15, and the subtracted values were plotted to calculate the K d values estimated using the one-site-specific binding equation in GraphPad Prism 7. All TR-FRET results are plotted as mean ± s.d. from three independent replicates (n = 3) unless otherwise indicated.
Crystallization. Frozen aliquots of the complex of Strep-II-Avi-DCAF15 NTD (residues 30-264), Strep-II-Avi-DCAF15 CTD (residues 383-600), His 6 -DDB1ΔB, His 6 -DDA1 and His 6 -RBM39 RRM2 complex were thawed, centrifuged for 10 min at 15,000 rpm at 4 °C and injected onto a Superdex 200 10/300 column equilibrated with 50 mM HEPES, pH 8.0, 150 mM NaCl, 2 mM TCEP and 20 μM E7820. All proteins used in crystallography are derived from human sequence. Peak fractions were pooled and concentrated at 4 °C to 56.8 μM (10 mg ml −1 ). Concentrated protein was supplemented with 25 μM E7820, and crystallization plates were dispensed as sitting drop with the Formulatrix NT8 at room temperature. Crystals appeared within one day and continued growing until day 4 when concentrated protein was mixed 2:1 or 1:1 with reservoir containing 200 mM lithium citrate tribasic and 20% (wt/vol) PEG 3350 in 96-well, 3-seat vapor diffusion Intelli-Plates (Art Robbins Instruments). For indisulam and tasisulam crystals, aliquots of the complex of Strep-II-Avi-DCAF15 NTD (residues 30-264), Strep-II-Avi-DCAF15 CTD (residues 383-600), His 6 -DDB1ΔB, His 6 -DDA1 and His 6 -RBM39 RRM2 complex bound to E7820 were thawed and then diluted and concentrated two times with buffer containing 20 μM indisulam or 30 μM tasisulam, respectively. The first dilution was with a fivefold excess of gel filtration buffer containing the appropriate compound and the second dilution was with a 15-fold excess of gel filtration buffer and compound. During the second dilution step, the protein complex was incubated on ice for 1 h to allow complete exchange of the compound before concentration. After the second concentration step, protein complexes were injected onto a Superdex 200 10/300 column equilibrated with 50 mM HEPES, pH 8.0, 150 mM NaCl, 2 mM TCEP and either 20 μM indisulam or 30 μM tasisulam. After gel filtration, purified protein was processed identically to E7820-bound complexes, as described above.
Crystals were cryo-protected in reservoir solution supplemented with 20% glycerol and flash frozen in liquid nitrogen. Diffraction data were collected at the APS Chicago (beamline 24-ID-C) with a Pilatus 6M-F detector at a temperature of 100 K and a wavelength of 0.9792 Å or 1.6531 Å. Data were indexed and integrated using XDS 31 and scaled using AIMLESS supported by other programs of the CCP4 suite 32 . Data processing statistics, refinement statistics and model quality parameters are provided in Supplementary Table 2 . Structure determination and model building. The DDB1ΔB-DCAF15 split -DDA1-E7820-RBM39 RRM2 , DDB1ΔB-DCAF15 split -DDA1-iodide-E7820 (5)-RBM39 RRM2 , DDB1ΔB-DCAF15 split -DDA1-indisulam-RBM39 RRM2 and DDB1ΔB-DCAF15 split -DDA1-tasisulam-RBM39 RRM2 complexes all crystallized in space group P2 1 2 1 2 1 with a single complex in the unit cell. PHASER 33 was used to determine the structures by molecular replacement using a crystallographic model of DDB1∆B based on a crystal structure pdb: 5fqd. Diffraction data for complexes containing compound 5 (iodide-E7820) or tasisulam were collected at 7500 eV and the MR-SAD pipeline (as implemented in Phaser 33 ) was used to obtain additional phase information, followed by density modification using parrot 32 . The initial model was iteratively improved with COOT 34 , using information from the density modified maps and sulfur anomalous difference peaks, and refined using PHENIX. REFINE 35 and autoBUSTER (https://www.globalphasing.com/buster/) with ligand restraints generated by Grade server (Global Phasing) or phenix.elbow 35 . Figures were generated with PyMOL (The PyMOL Molecular Graphics System, v.2.3.0, Schrödinger) and model quality was assessed with MOLPROBITY. Interaction surfaces were determined with PISA and conservation mapped using consurf 29 .
Sample preparation and cryo-EM data collection. The DDB1-DCAF15-E7820-RBM39 RRM2 complex was purified by gel filtration on a Superdex S200 10/300 column. A single peak fraction was collected and diluted to ~0.075 mg ml −1 . Proteome Discoverer 2.2 was used to analyze the LC-MS data. MS/MS spectra were searched against a truncated (~200 proteins) Uniprot human database (September 2016) with both the forward and reverse sequences. Database search criteria are as follows: tryptic or chymotryptic with two missed cleavages; a precursor mass tolerance of 10 ppm; fragment ion mass tolerance of 0.02 Da; static alkylation of cysteine (57.0211 Da); variable oxidation of methionine (15.9951 Da); variable phosphorylation of serine; threonine and tyrosine (79.966 Da); and variable acetylation (42.011 Da) of the protein N terminus and variable crosslinked 6 (possible adduct sizes: 422.141 Da or 83.049 Da) on all amino acids. Unique peptides were quantified in PD2.2 and the abundances of 6 modified peptides on DCAF15 for each of the treatments (DMSO, 6 (20 µM), and 6 (20 µM) with E7820 competition (100 µM)) were analyzed for potential modification sites.
Tandem mass tag LC-MS3 mass spectrometry. Kelly cells were treated with DMSO vehicle (triplicate) or 10 µM E7820 in singlicate for 5 h. Treated Kelly cells were washed in PBS (Corning VWR) and collected by centrifugation at 3,000g. Sample preparation and LC-MS analysis for whole-proteome identification of new E7820-dependent substrates was performed as described previously 9 .
Reporting Summary. Further information on research design is available in the Nature Research Reporting Summary linked to this article. 
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